AXQ Capital LP Cuts Stake in Altimmune, Inc. (NASDAQ:ALT)

AXQ Capital LP lessened its holdings in shares of Altimmune, Inc. (NASDAQ:ALT) by 47.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,388 shares of the company’s stock after selling 11,107 shares during the period. AXQ Capital LP’s holdings in Altimmune were worth $89,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in ALT. American Century Companies Inc. raised its stake in Altimmune by 35.8% in the fourth quarter. American Century Companies Inc. now owns 44,742 shares of the company’s stock valued at $323,000 after buying an additional 11,788 shares during the last quarter. Teacher Retirement System of Texas grew its position in Altimmune by 19.2% during the 4th quarter. Teacher Retirement System of Texas now owns 21,205 shares of the company’s stock worth $153,000 after purchasing an additional 3,423 shares during the last quarter. Intech Investment Management LLC increased its stake in Altimmune by 36.7% during the 4th quarter. Intech Investment Management LLC now owns 46,123 shares of the company’s stock valued at $333,000 after purchasing an additional 12,385 shares in the last quarter. Sequoia Financial Advisors LLC raised its holdings in shares of Altimmune by 34.5% in the fourth quarter. Sequoia Financial Advisors LLC now owns 13,655 shares of the company’s stock worth $98,000 after buying an additional 3,500 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Altimmune during the fourth quarter worth $88,000. Institutional investors and hedge funds own 78.05% of the company’s stock.

Insiders Place Their Bets

In other Altimmune news, CFO Gregory L. Weaver acquired 10,000 shares of the business’s stock in a transaction dated Thursday, March 13th. The stock was acquired at an average cost of $5.20 per share, for a total transaction of $52,000.00. Following the completion of the transaction, the chief financial officer now directly owns 10,000 shares of the company’s stock, valued at $52,000. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 4.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on ALT shares. Stifel Nicolaus began coverage on Altimmune in a research note on Wednesday, January 8th. They issued a “buy” rating and a $18.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a research note on Tuesday, March 18th. Finally, William Blair reiterated a “market perform” rating on shares of Altimmune in a research report on Friday, March 14th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.83.

Altimmune Trading Up 4.1 %

Shares of ALT stock opened at $6.05 on Tuesday. Altimmune, Inc. has a twelve month low of $5.14 and a twelve month high of $11.16. The stock has a market cap of $465.93 million, a P/E ratio of -3.90 and a beta of 0.87. The stock has a 50 day moving average of $6.32 and a 200 day moving average of $7.09.

Altimmune (NASDAQ:ALT) last posted its earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.01. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. On average, research analysts predict that Altimmune, Inc. will post -1.35 earnings per share for the current fiscal year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.